+

WO1997038578A1 - Stockage de materiaux - Google Patents

Stockage de materiaux Download PDF

Info

Publication number
WO1997038578A1
WO1997038578A1 PCT/GB1997/000993 GB9700993W WO9738578A1 WO 1997038578 A1 WO1997038578 A1 WO 1997038578A1 GB 9700993 W GB9700993 W GB 9700993W WO 9738578 A1 WO9738578 A1 WO 9738578A1
Authority
WO
WIPO (PCT)
Prior art keywords
plasma
blood plasma
dried
solids
drying
Prior art date
Application number
PCT/GB1997/000993
Other languages
English (en)
Inventor
Felix Franks
Anthony David Auffret
Barry John Aldous
Original Assignee
Inhale Therapeutic Systems
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inhale Therapeutic Systems filed Critical Inhale Therapeutic Systems
Priority to EP97916530A priority Critical patent/EP0892600A1/fr
Priority to AU25152/97A priority patent/AU732700B2/en
Priority to JP09536837A priority patent/JP2000514783A/ja
Publication of WO1997038578A1 publication Critical patent/WO1997038578A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00—Preservation of bodies of humans or animals, or parts thereof
    • A01N1/10—Preservation of living parts
    • A01N1/16—Physical preservation processes
    • A01N1/162—Temperature processes, e.g. following predefined temperature changes over time
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00—Preservation of bodies of humans or animals, or parts thereof
    • A01N1/10—Preservation of living parts

Definitions

  • This invention relates to the storage of materials, more specifically blood plasma.
  • materials more specifically blood plasma.
  • EP-A-520748 it is explained that unstable biological materials can be placed in a stable form by spray drying them in the presence of an appropriate carrier substance which, when dried leads to a composition in the form of a glassy or rubbery amorphous state.
  • an appropriate carrier substance which, when dried leads to a composition in the form of a glassy or rubbery amorphous state.
  • the_material which is to be stored may occur in a form which already incorporates a suitable carrier substance, "and" in particular that this situation may arise with products derived from blood plasma where the material to be stored is a relatively minor component of the blood plasma and other components which naturally occur in the blood plasma, notably albumin, are able to form a glass on drying.”
  • Whole blood such as given by a human blood donor, is routinely separated into a fraction which contains erythrocytes and a fraction which is blood plasma without erythrocytes. Both of these materials can be used for transfusion into a patient. It is also possible to fractionate the blood plasma further, to isolate specific components, and use the required component in therapy.
  • Blood plasma cannot be stored at room temperature but can be frozen and stored indefinitely as the frozen material. Many hospitals have facilities for storing such frozen blood plasma.
  • dried blood plasma This will be a composition, in the form of an amorphous glass or rubber (as to have the appearance of a solid) containing the solids of blood plasma.
  • This composition is preferably in the form of an amorphous powder and may have a glass transition temperature of at least 15 * C, better at least 20 * C or above.
  • the composition may possibly contain an added carrier material, mixed with the plasma solids. However, we have found that such an added carrier may be omitted, or may be present in an amount which is less than the weight of added plasma. Even when some carrier is added, the composition preferably contains at least 75% by weight plasma solids, better at least 80 or 90%.
  • the glass transition temperature of blood plasma dried to a low moisture content and without added carrier is higher than would be predicted from the glass transition temperature of dried human albumin, even though albumin is a major constituent of the solutes in blood plasma.
  • a preferred form of product is blood plasma, dried without addition of extra carrier substance, and having a glass transition temperature of at least 20 "C, better at least 25 * C or at least 30°C.
  • composition may be such as to require minimal processing before transfusion.
  • the blood plasma may be packaged in individual quantities of such a size as will give an appropriate volume for transfusion when rehydrated. Such a quantity may well be such as will require between 50 and- 1000 ml, more likely between 100 and 500 ml of water for rehydration to the original concentration found in blood plasma.
  • the published value for the mean solids content of plasma is 8.6% by weight. Consequently, such an individual dose may contain plasma solids in a quantity between 4.3 and 86 grams, more likely between 8.6 and 43 grams.
  • a method of rendering blood plasma suitable for storage which comprises spraying blood plasma into a hot gas stream, thereby drying the blood plasma to particles which are in a glassy or rubbery amorphous state and separating these particles from the gas stream.
  • a glass is defined as an undercooled liquid with a very high viscosity, that is to say at least 10 Pa. s, probably 1014 Pa. s or more,
  • a glass presents the appearance of a homogeneous, transparent, brittle solid which can be ground or milled to a powder.
  • diffusive processes take place at extremely low rates, such as microns per year. Chemical or biochemical changes involving more than one reacting moiety are practically inhibited.
  • T g a temperature known as the glass transition temperature T g .
  • hydrophilic materials either water-soluble or water-swellable, both of a monomeric and a polymeric nature either exist in an amorphous state or can be converted into such an amorphous state which exhibit the glass/rubber transitions characteristic of amorphous macromolecules. They have well- defined glass transition temperatures T g which depend on the molecular weight and on molecular complexity of the substance concerned. T is depressed by the addition of plasticisers . Water is a universal plasticiser for all such hydrophilic materials. Therefore, the glass/rubber transition temperature is adjustable by the addition of water or an aqueous solution.
  • the blood plasma may be obtained by conventional techniques for the separation of blood plasma from whole blood. Because of fears of virus infection, it is nowadays conventional that blood plasma is subjected to a treatment to inactivate any viruses present. (This may entail exposure of the blood plasma to solvent and to surfactant . ) Blood plasma which has been virus-inactivated in this way may be used.
  • the blood plasma may be "whole" plasma in that it contains all the water-soluble constituents of blood (except gases) in their natural proportions relative to each other, although with their concentrations changed by the separation of erythrocytes and possibly by dilution with anticoagulant solution.
  • the blood plasma may, if desired, be stored temporarily in the frozen state prior to drying. This may be found to be more convenient than carrying out the drying operation on freshly obtained blood plasma.
  • At least 90% by weight of the dried plasma preferably at least 95%, will be solutes from natural plasma.
  • any carrier substance should be a material which is hydrophilic so that it is either water-soluble or water-swellable and is such that it can exist in an amorphous state.
  • carbohydrates are an important group of glass forming substances: thus candy is a glassy form of sugar (glucose or sucrose) .
  • the T g for glucose, maltose and maltotriose are respectively 31, 43 and 76°C. (L. Slade and H. Levine, Non-equilibrium behaviour of small carbohydrate-water systems, Pure Appl. Chem. 6_0 1841
  • polyhydroxy compounds can be used, such as carbohydrate derivatives and chemically modified carbohydrates (i.e. carbohydrates which have undergone chemical reaction to alter substituents on the carbon backbone of the molecule but without alteration of that backbone) .
  • carbohydrate derivatives i.e. carbohydrates which have undergone chemical reaction to alter substituents on the carbon backbone of the molecule but without alteration of that backbone
  • Another important class of glass forming substances are water-soluble or water-swellable synthetic polymers, such as polyacrylamide.
  • albumin can be used, and so can hydrolysis products of- gelatin.
  • a further group of glass forming substances which may in particular be employed are sugar copolymers described in US Patent 3 300 474 and sold by Pharmacia under the Registered Trade Mark “Ficoll”.
  • This US patent describes the materials as having molecular weight 5,000 to 1,000,000 and containing sucrose residues linked through ether bridges to bifunctional groups.
  • Such groups may be alkylene of 2, 3 or more carbon atoms but not normally more than 10 carbon atoms.
  • the bifunctional groups serve to connect sugar residues together.
  • These polymers may for example be made by reaction of the sugar with a halohydrin or a bis-epoxy compound.
  • T values can be determined with a differential scanning calorimeter and can be detected as a point at which a plot of heat input against temperature passes through an inflection point - giving a maximum of the first temperature derivative.
  • Processing begins with either liquid blood plasma or a mixture of such liquid blood plasma and an added carrier substance.
  • the next step is a spray drying operation in which the aqueous mixture is sprayed into a hot gas stream.
  • the gas employed will generally be air but it could be some other gas such as nitrogen. If the blood plasma will eventually be used in transfusion, the gas used to provide the hot gas stream should be sterile. Apparatus for the filtration of gas to render it sterile is commercially available and is routinely used in the pharmaceutical industry.
  • the spray drying of blood plasma can be carried out effectively by spray drying the blood plasma (or mixture of blood plasma and added carrier) into a hot gas stream with a temperature in the range of 80 * C to 250 * C, better 125 * C to 250 * C.
  • a laboratory scale spray dryer may well dry blood plasma to an amorphous powder with a small residual moisture content such that the amorphous powder displays a glass transition temperature in the range from -20 * C to 20 * C.
  • the addition of a carrier substance may make it easier to obtain a higher value of T g in the spray drying operation.
  • the added carrier substance is a glass forming material which, on its own, has a glass transition temperature of at least 40"C, better at least 50 * C. While there is no theoretical upper limit on the glass transition temperature for an added carrier material, in practice suitable materials have values of T g below 250 * C. Consequently if a carrier substance is added to the blood plasma it will frequently be the case that the glass transition temperature of this material when pure and amorphous lies in a range from 50 to 200 * C.
  • Larger scale spray drying apparatus may well be able to dry blood plasma directly to a product with a T value of at least 15 * C or 20 * C even without any separate addition of carrier material to the blood plasma.
  • Apparatus to carry out spray drying on a fairly small scale is available from various manufacturers.
  • One is Drytec Ltd, Tonbridge, Kent, England who manufacture a pilot plant scale dryer.
  • Another manufacturer is Lab-Plant Ltd of Longwood, Huddersfield, England who manufacture a laboratory scale dryer.
  • Process plant to carry out spray drying on a larger scale is also well known.
  • the spray dried blood plasma can be stored for a long time, provided the storage temperature is below the T g of the amorphous dried plasma.
  • ⁇ _ of the dried plasma is sufficient high, storage can be at room temperature. However, if T g is close to or below room temperature it may be necessary or desirable.to refrigerate the dried plasma in cooled or refrigerated storage, especially if storage is for a prolonged period. This is less convenient but nevertheless requires less refrigeration capacity than does the storage of frozen plasma.
  • blood plasma is dried to an amorphous state with a glass transition temperature below 15 * C it may be desired to keep it in refrigerated storage, at a temperature below 5 * C, to keep it below the glass transition temperature of the material.
  • the dried blood plasma When required for use the dried blood plasma can be reconstituted by the addition of water or possibly aqueous saline solution. It will generally be desired that the water which is used is sterile so that if the spray drying was also carried out under sterile conditions the reconstituted blood plasma is in a sterile condition for use in transfusion. Apparatus for the purification of water to a sterile state is of course readily available.
  • the sole drawing is a diagrammatic illustration of laboratory scale spray-drying apparatus.
  • the droplets of spray are dried to solid powder form as they pass down within the main chamber 16.
  • the powder is entrained in the air which has passed down the main chamber 16. This leaves by an exit tube 26 at one side delivering to a cyclone separator 28 which serves to remove entrained solid particles from the air stream.
  • the solid particles which are separated from the air stream in this way are collected as the product in a detachable vessel 30 while the air passes out to atmosphere through an exhaust tube 32. Solids which stick to the wall of the main chamber fall into waste container 24.
  • a significant parameter in the operation of any spray drying apparatus is the temperature of the gas stream which is admitted to the main chamber and into which the spray is delivered.
  • this inlet temperature of the gas stream will generally exceed 80 * C, will usually exceed 90 * C and may well lie in a range from 100 to 250/300 * C.
  • Albumin constitutes the largest single protein component (3-5% w/v) of plasma; it was therefore used as a model substance.
  • An aqueous solution containing 299 mg/ml of human albumin, was diluted with distilled water to give a solution that contained 125 mg/ml of the protein.
  • Portions of 2ml were pipetted into vials and frozen to - 37 * C in a freeze-drier.
  • the temperature was maintained constant and the pressure was reduced to 0.21 mbar.
  • the ice was completely sublimed during a period of 14 hours.
  • the pressure was then reduced to 0.12 mbar and secondary drying was performed by ramping the temperature at a rate of 5 deg/hour to 30'C.
  • the product was maintained at that temperature for 2 hours.
  • One Unit (200ml) of frozen, virus-inactivated human plasma was thawed. Of the thawed plasma, 5ml was refrozen, to serve as control for subsequent assay. The remaining 195ml was added to 34ml distilled water and spray dried, using a Lab Plant Spray Drier, Model SD-04, the construction of which as shown in the drawing.
  • the liquid plasma was pumped into the main chamber at a rate of 425 ml/h, being injected through a nozzle of 0.5mm diameter under a pressure of ⁇ 2 bar.
  • the hot air was introduced into the chamber in a co-current manner, at a rate of 62 m 3 /h and a temperature of 200 * C.
  • the outlet air had a temperature of 81 * C.
  • the collected material was a straw- coloured, free-flowing powder.
  • the yield of dried plasma collected was 72.5% of the amount predicted from the published mean solids content of plasma (8.6% by weight) . It was stored in a plasma bottle at -40 °C for two months, before carrying out assay as described below.
  • One Unit (200ml) of frozen, virus-inactivated human plasma was thawed. Of the thawed plasma, 5ml was refrozen, to serve as control for subsequent assay. The remaining 195ml was added to 34ml distilled water and spray dried, using a Lab Plant Spray Drier, Model SD-04, as follows: The liquid plasma was pumped into the chamber at a rate of 350 ml/h, being injected through a nozzle of 0.5mm diameter under a pressure of ⁇ 2 bar. The hot air was introduced into the chamber in a co-current manner, at a rate of 64 m 3 /h and a temperature of 150'C. The outlet air had a temperature of 81 * C. The collected material was a pale yellow, free-flowing powder. The yield of dried plasma collected was 79.8% of the amount predicted. It was stored in a plasma bottle at -40 * C for two months, before carrying out assay as described below.
  • One Unit (200ml) of frozen, virus-inactivated human plasma was thawed. Of the thawed plasma, 5ml was refrozen, to serve as control for subsequent assay. The remaining 195ml were spray dried, using a Lab Plant Spray Drier, Model SD-05, fitted with a scrubber to remove any entrained material from the exhaust gas.
  • the liquid plasma was pumped into the main drying chamber at a rate of 175 ml/h, being injected through a nozzle of 0.5mm diameter under a pressure of ⁇ 2 bar.
  • the hot air was introduced into the chamber in a co-current manner, at a rate of 52 m 3 /h and a temperature of 200 * C.
  • the outlet air had a temperature of 91°C.
  • the collected material was a straw coloured, free- flowing powder. The yield of dried plasma collected was 68%.
  • One Unit (200ml) of frozen, virus-inactivated human plasma was thawed. Of the thawed plasma, 5ml was refrozen, to serve as control for subsequent assay. The remaining 195ml was added to 34ml distilled water which contained lOg sucrose of food grade and spray dried, using a Lab Plant Spray Drier, Model SD-04, as follows: The liquid mixture was pumped into the chamber at a rate of 425 ml/h, being injected through a nozzle of 0.5mm diameter under a pressure of ⁇ 2 bar. The hot air was introduced into the chamber in a co-current manner, at a rate of 62 m 3 /h and a temperature of 200'C. The outlet air had a temperature of 82"C. The collected material was a straw coloured, free- flowing powder. The yield of dried plasma collected was 74.3%. It was stored in a plasma bottle at -40'C for two months, before assay.
  • Samples of blood plasma dried by procedures similar to Examples 2 to 5 were also taken (on dry ice) to a different laboratory, stored there for 5 months at -lOO'C, and analysed for the content of Factor VIII. The amount present was found to be slightly greater than the amount in control samples of blood plasma which had been stored frozen without drying.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Dentistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Environmental Sciences (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

L'invention se rapporte au stockage de plasma sanguin, séché jusqu'à un état amorphe, sa température de transition vitreuse étant d'au moins 15 °C. La température de transition vitreuse du plasma sanguin séché est plus élevée que prévu. Par conséquent, même si on mélange un matériau porteur au plasma et si on l'inclut dans la composition vitreuse séchée, le poids du plasma solidifié peut dépasser le poids du matériau porteur, quel que soit ce dernier. Etant donné qu'un matériau porteur ajouté peut n'être présent qu'en faibles quantités ou être absent, la composition séchée peut prendre la forme d'une dose unitaire qu'il faut seulement réhydrater avant de transfuser.
PCT/GB1997/000993 1996-04-12 1997-04-10 Stockage de materiaux WO1997038578A1 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP97916530A EP0892600A1 (fr) 1996-04-12 1997-04-10 Stockage de materiaux
AU25152/97A AU732700B2 (en) 1996-04-12 1997-04-10 Storage of materials
JP09536837A JP2000514783A (ja) 1996-04-12 1997-04-10 物質の貯蔵

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9607636.9 1996-04-12
GBGB9607636.9A GB9607636D0 (en) 1996-04-12 1996-04-12 Storage of materials

Publications (1)

Publication Number Publication Date
WO1997038578A1 true WO1997038578A1 (fr) 1997-10-23

Family

ID=10791980

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB1997/000993 WO1997038578A1 (fr) 1996-04-12 1997-04-10 Stockage de materiaux

Country Status (6)

Country Link
EP (1) EP0892600A1 (fr)
JP (1) JP2000514783A (fr)
AU (1) AU732700B2 (fr)
CA (1) CA2251333A1 (fr)
GB (1) GB9607636D0 (fr)
WO (1) WO1997038578A1 (fr)

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102006011534A1 (de) * 2006-03-14 2007-09-20 Johannes-Gutenberg-Universität Mainz Plasma-Lyophilisat
US8407912B2 (en) 2010-09-16 2013-04-02 Velico Medical, Inc. Spray dried human plasma
US8533972B2 (en) 2010-10-29 2013-09-17 Velico Medical, Inc. System and method for spray drying a liquid
US9867782B2 (en) 2009-04-09 2018-01-16 Entegrion, Inc. Spray-dried blood products and methods of making same
US10251911B2 (en) 2009-09-16 2019-04-09 Entegrion, Inc. Spray dried human plasma
US10843100B2 (en) 2010-10-29 2020-11-24 Velico Medical, Inc. Spray drier assembly for automated spray drying
US11052045B2 (en) 2014-09-19 2021-07-06 Velico Medical, Inc. Formulations and methods for contemporaneous stabilization of active proteins during spray drying and storage
US11841189B1 (en) 2022-09-15 2023-12-12 Velico Medical, Inc. Disposable for a spray drying system
US11975274B2 (en) 2022-09-15 2024-05-07 Velico Medical, Inc. Blood plasma product
US11998861B2 (en) 2022-09-15 2024-06-04 Velico Medical, Inc. Usability of a disposable for a spray drying plasma system
US12083447B2 (en) 2022-09-15 2024-09-10 Velico Medical, Inc. Alignment of a disposable for a spray drying plasma system
US12246266B2 (en) 2022-09-15 2025-03-11 Velico Medical, Inc. Disposable for a spray drying system
US12246093B2 (en) 2022-09-15 2025-03-11 Velico Medical, Inc. Methods for making spray dried plasma

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5145706A (en) * 1991-03-28 1992-09-08 Taiyo Kagaku Co., Ltd. Method for preparation of plasma powder and product thereof
EP0520748A1 (fr) * 1991-06-26 1992-12-30 Pafra Limited Emmagasinage de matériaux
WO1993014191A1 (fr) * 1992-01-21 1993-07-22 Cryopharm Corporation Procede de congelation de cellules et de matieres analogues a des cellules

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5145706A (en) * 1991-03-28 1992-09-08 Taiyo Kagaku Co., Ltd. Method for preparation of plasma powder and product thereof
EP0520748A1 (fr) * 1991-06-26 1992-12-30 Pafra Limited Emmagasinage de matériaux
WO1993014191A1 (fr) * 1992-01-21 1993-07-22 Cryopharm Corporation Procede de congelation de cellules et de matieres analogues a des cellules

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
R. RAMANUJAM ET AL: "Stabilization of nucleic acids in whole blood: an alternative to Guthrie-cards.", BIOTECHNIQUES, vol. 15, no. 5, 1993, NATICK US, pages 825 - 828, XP002034861 *

Cited By (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102006011534A1 (de) * 2006-03-14 2007-09-20 Johannes-Gutenberg-Universität Mainz Plasma-Lyophilisat
US9867782B2 (en) 2009-04-09 2018-01-16 Entegrion, Inc. Spray-dried blood products and methods of making same
US11213488B2 (en) 2009-04-09 2022-01-04 Entegrion, Inc. Spray-dried blood products and methods of making same
US12208121B2 (en) 2009-09-16 2025-01-28 Velico Medical, Inc. Spray-dried human plasma
US10251911B2 (en) 2009-09-16 2019-04-09 Entegrion, Inc. Spray dried human plasma
US8407912B2 (en) 2010-09-16 2013-04-02 Velico Medical, Inc. Spray dried human plasma
US8434242B2 (en) 2010-09-16 2013-05-07 Velico Medical, Inc. Spray dried human plasma
US8601712B2 (en) 2010-10-29 2013-12-10 Velico Medical, Inc. System and method for spray drying a liquid
US10843100B2 (en) 2010-10-29 2020-11-24 Velico Medical, Inc. Spray drier assembly for automated spray drying
US8595950B2 (en) 2010-10-29 2013-12-03 Velico Medical, Inc. System and method for spray drying a liquid
US8533971B2 (en) 2010-10-29 2013-09-17 Velico Medical, Inc. System and method for spray drying a liquid
US8533972B2 (en) 2010-10-29 2013-09-17 Velico Medical, Inc. System and method for spray drying a liquid
US12064518B2 (en) 2014-09-19 2024-08-20 Velico Medical, Inc. Formulations and methods for contemporaneous stabilization of active proteins during spray drying and storage
US11052045B2 (en) 2014-09-19 2021-07-06 Velico Medical, Inc. Formulations and methods for contemporaneous stabilization of active proteins during spray drying and storage
US11806431B2 (en) 2014-09-19 2023-11-07 Velico Medical, Inc. Formulations and methods for contemporaneous stabilization of active proteins during spray drying and storage
US11913723B1 (en) 2022-09-15 2024-02-27 Velico Medical, Inc. Baffle plate used in a disposable for a spray drying system
US11975274B2 (en) 2022-09-15 2024-05-07 Velico Medical, Inc. Blood plasma product
US11998861B2 (en) 2022-09-15 2024-06-04 Velico Medical, Inc. Usability of a disposable for a spray drying plasma system
US11913722B1 (en) 2022-09-15 2024-02-27 Velico Medical, Inc. Rapid spray drying system
US12083447B2 (en) 2022-09-15 2024-09-10 Velico Medical, Inc. Alignment of a disposable for a spray drying plasma system
US12092397B2 (en) 2022-09-15 2024-09-17 Velico Medical, Inc. Disposable for a spray drying system
US12201920B2 (en) 2022-09-15 2025-01-21 Velico Medical, Inc. Blood plasma product
US11841189B1 (en) 2022-09-15 2023-12-12 Velico Medical, Inc. Disposable for a spray drying system
US12246266B2 (en) 2022-09-15 2025-03-11 Velico Medical, Inc. Disposable for a spray drying system
US12247784B2 (en) 2022-09-15 2025-03-11 Velico Medical, Inc. Baffle plate used in a disposable for a spray drying system
US12246093B2 (en) 2022-09-15 2025-03-11 Velico Medical, Inc. Methods for making spray dried plasma
US12253308B1 (en) 2022-09-15 2025-03-18 Velico Medical Inc. Disposable for a spray drying system
US12274955B2 (en) 2022-09-15 2025-04-15 Velico Medical, Inc Usability of a disposable for a spray drying plasma system

Also Published As

Publication number Publication date
JP2000514783A (ja) 2000-11-07
AU2515297A (en) 1997-11-07
CA2251333A1 (fr) 1997-10-23
EP0892600A1 (fr) 1999-01-27
GB9607636D0 (en) 1996-06-12
AU732700B2 (en) 2001-04-26

Similar Documents

Publication Publication Date Title
CA2072420C (fr) Procede de stockage de matieres
AU732700B2 (en) Storage of materials
US20220106357A1 (en) Plasma fractionation utilizing spray-dried human plasma
US6503411B1 (en) Stable compositions
US5877005A (en) Viral inactivation method using near critical, supercritical or critical fluids
JP2006512102A (ja) 噴霧乾燥による生物活性材料の防腐
AU2007231918B2 (en) Preservation of bioactive materials by freeze dried foam
US20120082715A1 (en) Stabilized products, processes and devices for preparing the same
EP0728195A1 (fr) Procedes de conservation de virus de recombinaison
AU2011290609B2 (en) Blood plasma lyophilization process
AU2003200950A1 (en) Method for Reconstituting Lyophilized Proteins
AU2008201720B2 (en) High pressure spray-dry of bioactive materials

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU CA JP US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 1997916530

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2251333

Country of ref document: CA

Ref country code: CA

Ref document number: 2251333

Kind code of ref document: A

Format of ref document f/p: F

WWP Wipo information: published in national office

Ref document number: 1997916530

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1997916530

Country of ref document: EP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载